Resumo:
In view of the high frequency of involvement, morbidity and mortality in female dogs
with mammary tumors, an integrative treatment was sought that could promote an
improvement in the antioxidant response and quality of life of these animals. In this
context, the objective was to evaluate the oxidative profile: through the total antioxidant
capacity (TAC) and the concentration of malondialdehyde (MDA), the clinical and
laboratory response (red blood cells, platelets, relative and absolute lymphocytes, urea,
creatinine, alanine aminotransferase and alkaline phosphatase) and the quality of life
score of patients before and after mastectomy. A total of 180 female dogs were evaluated.
Of these, 49 were selected and divided into five groups, one group as a control healthy
group (GH): healthy dogs, with no history of breast tumors; and four experimental groups:
mastectomy Group (GM): dogs with breast tumor submitted only to mastectomy; GMO3:
female dogs with breast tumor, submitted to mastectomy and ozone therapy (ozonated
minor autohemotherapy) at the VG14 acupoint (dahzhui) in the pre and postoperative
periods; GMAHT: dogs with breast tumor, submitted to mastectomy and
autohemotherapy at acupoint VG14, in the pre and postoperative periods and GMA: dogs
with breast tumor, submitted to mastectomy and acupuncture at acupoint VG14, in the
same periods. The use of ozone therapy and the quality of life score were evaluated in
comparison with the other experimental groups in five moments: initial clinical
evaluation (D0); preoperative evaluation (D1); mastectomy (D2); evaluation of the
surgical wound (D3) and removal of surgical stitches (D4). Three of the moments (D0,
D2 and D4) were considered main, for the evaluation of the oxidative profile and two of
them (D0 and D4), for the hematological parameters. There was a significant increase in
the quality of life score, from D0 (26.4) to D2 (27.5) and to D4 (32). In the oxidative
profile of GMO3, from D0 to D4, there was a progressive increase in the global mean
TAC from 12.74 to 19.39 and a reduction in MDA from 446.1 to 150.5. In the
hematological profile, related to renal function, there was a reduction in the global
average of creatinine (p=0.009), in D0 from D4. The evaluation of the epidemiological clinical parameters showed a statistically significant association between ozone therapy
and an increase in antioxidant capacity, a reduction in oxidative stress and an increase in
the quality of life score. GMO3 performed better than the other experimental groups
studied (GM, GMAHT and GMA). The evaluated results suggest that ozonized
autohemotherapy, before and after mastectomy, represented a viable, economical and safe
treatment possibility to optimize the antioxidant response, reduce oxidative damage and,
consequently, provide a better quality of life for patients with breast cancer.
